Success Metrics

Clinical Success Rate
85.2%

Based on 23 completed trials

Completion Rate
85%(23/27)
Active Trials
2(7%)
Results Posted
74%(17 trials)
Terminated
4(13%)

Phase Distribution

Ph phase_4
4
13%
Ph phase_2
10
33%
Ph not_applicable
6
20%
Ph phase_3
5
17%
Ph phase_1
4
13%

Phase Distribution

4

Early Stage

10

Mid Stage

9

Late Stage

Phase Distribution29 total trials
Phase 1Safety & dosage
4(13.8%)
Phase 2Efficacy & side effects
10(34.5%)
Phase 3Large-scale testing
5(17.2%)
Phase 4Post-market surveillance
4(13.8%)
N/ANon-phased studies
6(20.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

85.2%

23 of 27 finished

Non-Completion Rate

14.8%

4 ended early

Currently Active

2

trials recruiting

Total Trials

30

all time

Status Distribution
Active(2)
Completed(23)
Terminated(4)
Other(1)

Detailed Status

Completed23
Terminated4
Active, not recruiting1
unknown1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
30
Active
2
Success Rate
85.2%
Most Advanced
Phase 4

Trials by Phase

Phase 14 (13.8%)
Phase 210 (34.5%)
Phase 35 (17.2%)
Phase 44 (13.8%)
N/A6 (20.7%)

Trials by Status

active_not_recruiting13%
completed2377%
terminated413%
unknown13%
recruiting13%

Recent Activity

2 active trials
Showing 5 of 30
terminatednot_applicable

Effect of Guanfacine on the Reversal of Opioid-induced Hyperalgesia (OIH)

NCT02192398
recruitingphase_2

ACE-D Aim 3 Clinical Cognitive Trial to Enhance Translation in Depression

NCT06408246
completedphase_2

Maximizing trEatment of Neurological Dysfunction Using INtravenous Guanfacine Study

NCT04742673
completedphase_3

The Effect of Guanfacine on Delirium in Critically Ill Patients

NCT04578886
completedphase_2

Efficacy of Guanfacine and Lidocaine Combination in Trigeminal Nerve Block for Pain Management in Trigeminal Neuropathy

NCT03865940
View all 30 trials

Clinical Trials (30)

Showing 20 of 30 trialsScroll for more
NCT02192398Not Applicable

Effect of Guanfacine on the Reversal of Opioid-induced Hyperalgesia (OIH)

Terminated
NCT06408246Phase 2

ACE-D Aim 3 Clinical Cognitive Trial to Enhance Translation in Depression

Recruiting
NCT04742673Phase 2

Maximizing trEatment of Neurological Dysfunction Using INtravenous Guanfacine Study

Completed
NCT04578886Phase 3

The Effect of Guanfacine on Delirium in Critically Ill Patients

Completed
NCT03865940Phase 2

Efficacy of Guanfacine and Lidocaine Combination in Trigeminal Nerve Block for Pain Management in Trigeminal Neuropathy

Completed
NCT03116126Phase 3

Noradrenergic Add-on Therapy With Guanfacine

Active Not Recruiting
NCT03980184Phase 2

Guanfacine to Improve Substance Use Outcomes in Women

Completed
NCT02259517Not Applicable

An fMRI Study of Stimulant vs. Non-Stimulant Treatment of ADHD

Terminated
NCT00773357Phase 2

Modeling Stress-precipitated Smoking Behavior for Medication Development

Completed
NCT02051309Phase 2

Guanfacine Clinical Trial for Smoking Cessation

Completed
NCT00429273Phase 4

Single Versus Combination Medication Treatment for Children With Attention Deficit Hyperactivity Disorder

Completed
NCT02699125Phase 4

Treatment of OSA Associated Hypertension With Alpha 2 Agonist or Diuretic

Completed
NCT04016207

Affective Dysregulation (AD) in Children With ADHD Treated by Guanfacin

Unknown
NCT01904526Phase 2

PK/PD Comparison of Guanfacine ER and IR

Completed
NCT00955253Phase 2

Guanfacine for the Treatment of Spatial Neglect and Impaired Vigilance

Completed
NCT01467999Phase 1

Open-Label Pilot Study of Guanfacine-Extended Release for the Treatment of Cannabis Dependence

Completed
NCT02882854Not Applicable

Guanfacine for PONV and Pain After Sinus Surgery

Completed
NCT00613015Phase 2

Stress and Medication Effects on Cocaine Cue Reactivity

Completed
NCT00223717Phase 1

Treatment of Supine Hypertension in Autonomic Failure

Completed
NCT01600885Not Applicable

The Effects of Ketamine and Guanfacine on Working Memory in Healthy Subjects

Completed

Drug Details

Intervention Type
DRUG
Total Trials
30